1. Home
  2. NGNE vs MPX Comparison

NGNE vs MPX Comparison

Compare NGNE & MPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • MPX
  • Stock Information
  • Founded
  • NGNE 2003
  • MPX 1965
  • Country
  • NGNE United States
  • MPX United States
  • Employees
  • NGNE N/A
  • MPX N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • MPX Marine Transportation
  • Sector
  • NGNE Health Care
  • MPX Industrials
  • Exchange
  • NGNE Nasdaq
  • MPX Nasdaq
  • Market Cap
  • NGNE 325.3M
  • MPX 312.9M
  • IPO Year
  • NGNE N/A
  • MPX N/A
  • Fundamental
  • Price
  • NGNE $18.48
  • MPX $8.79
  • Analyst Decision
  • NGNE Strong Buy
  • MPX
  • Analyst Count
  • NGNE 7
  • MPX 0
  • Target Price
  • NGNE $41.86
  • MPX N/A
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • MPX 19.7K
  • Earning Date
  • NGNE 08-11-2025
  • MPX 10-23-2025
  • Dividend Yield
  • NGNE N/A
  • MPX 6.41%
  • EPS Growth
  • NGNE N/A
  • MPX N/A
  • EPS
  • NGNE N/A
  • MPX 0.40
  • Revenue
  • NGNE N/A
  • MPX $224,368,000.00
  • Revenue This Year
  • NGNE N/A
  • MPX $3.97
  • Revenue Next Year
  • NGNE N/A
  • MPX $13.02
  • P/E Ratio
  • NGNE N/A
  • MPX $21.83
  • Revenue Growth
  • NGNE N/A
  • MPX N/A
  • 52 Week Low
  • NGNE $6.88
  • MPX $7.49
  • 52 Week High
  • NGNE $74.49
  • MPX $10.32
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • MPX 53.47
  • Support Level
  • NGNE $19.59
  • MPX $8.66
  • Resistance Level
  • NGNE $20.46
  • MPX $9.10
  • Average True Range (ATR)
  • NGNE 1.23
  • MPX 0.26
  • MACD
  • NGNE -0.20
  • MPX 0.02
  • Stochastic Oscillator
  • NGNE 13.37
  • MPX 72.63

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About MPX Marine Products Corporation

Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. It operates in the powerboat manufacturing business segment in Nashville, Valdosta, and Georgia. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.

Share on Social Networks: